drugset / Trial / NCT06764927
Fibrinogen in Liver Transplant Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of Investigational Cryoprecipitate Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.
Timeline
- Start
- 2026-01-31
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
Outcome
Outcome not reported
Stopped: “No supply of the test substance was provided by the sponsor.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Antihemophilic Factor | Unknown | — | — |
| Comparator | INTERCEPT Fibrinogen Complex | Protein / enzyme biologic | — | — |
Indications
No indication recorded.